Norroy Bioscience Showcased Integrated Radiopharmaceutical Solutions at EANM 2025
The 2025 European Association of Nuclear Medicine (EANM) Annual Congress successfully concluded in Barcelona. Over 10,000 participants attended the Congress with more than 150 academic sessions covering key topics, such as theranostics, radiopharmaceutical development, and molecular imaging.
At Booth No. 67, Norroy Bioscience presented its global integrated solutions for radiopharmaceuticals, highlighting the comprehensive automation offerings from its subsidiary Mortenon, which span across the entire nuclear medicine production and supply chain. The booth attracted close to a hundred professional visits, leading to dozens of potential partnerships, which underscore the rising influence of China’s original innovations for radiopharmaceuticals and intelligent manufacturing on the global stage.
Norroy’s exhibition showcased the company’s capabilities in providing multidimensional solutions, from raw material synthesis to intelligent delivery. The Mortenon Series of products drew particular attention for its end-to-end solutions covering raw material breakthroughs, high-end equipment integration, modular “super factory” design, and I-o-T-enabled precision logistics — driving the transition of radiopharmaceutical industry from traditional manufacturing to intelligent production.
In the academic sessions, Norroy scientists presented four oral reports, featuring the updates on the NY104 renal cancer pipeline and the company’s emerging FAP-targeted radiopharmaceutical program, both of which drew strong interests from the scientific community.
Professor Hongcheng Shi, Vice President of Chinese Society of Nuclear Medicine (pictured right), visited the Norroy booth and met with Mr. Peng Fang, Founder and Chairman of Norroy Bioscience (pictured left).
“We are delighted to present Norroy’s integrated radiopharmaceutical solutions on this global stage,” said Mr. Peng Fang, Founder and Chairman of Norroy Bioscience. “As the worldwide radiopharmaceutical market continues to grow, the competition has expanded beyond R&D into comprehensive capabilities across the entire value chain — including efficient clinical translation, manufacturing scalability, and supply chain robustness. Leveraging our proprietary technology platforms and resource integration strengths, Norroy is accelerating the research, development and commercialization of China’s original radiopharmaceuticals to make the precision oncological treatments more accessible globally.”
Recognized as one of the most influential academic events in nuclear medicine, EANM plays a key role in shaping the international clinical standards, with its guidelines widely adopted as the global references for nuclear medicine practice.
